Literature DB >> 21305388

Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice.

Xiaorong Zhou1, Xing Hua, Xiaoling Ding, Yonghua Bian, Xiaoying Wang.   

Abstract

OBJECTIVE: Histone deacetylase inhibitors have shown suppressive effects on tumor growth and in some autoimmune diseases. However, the molecular mechanisms of their effects are not very clear. The purpose of this study was to investigate the effects of trichostatin A (TSA) on collagen-induced rheumatoid arthritis (CIA) in a mouse model and its underlying mechanisms.
METHODS: CIA was induced in DBA/1 mice with type II collagen. Paws were scored to assess disease severity. Inflammation of joints was evaluated by histological examination. Real-time PCR was used to determine cytokine mRNA levels. Cytokine production in serum and in supernatants from dendritic to T cell co-cultures was measured by ELISA. T cell proliferation was determined using [(3)H] incorporation. Intracellular cytokine staining was used to measure interferon gamma (IFN-γ)- and interleukin (IL)-4-producing T cells in splenocytes. Chromatin immunoprecipitation was used to examine histone H3 and H4 acetylation.
RESULTS: TSA potently suppressed the severity of arthritis and type II collagen-specific T cell responses in CIA. IFN-γ expression was high in CIA mice, but was inhibited by TSA treatment either at the same time as immunization or at the onset of arthritis manifestation. T cells from TSA-treated mice produced higher levels of IL-4 than cells from the control group. TSA predominantly suppressed Th1 cell proliferation in vitro by induction of apoptosis. In addition, TSA enhanced IL-4 gene expression of in vitro differentiated Th2 cells, and the mechanism is associated with an increased level of histone acetylation in the IL-4 gene promoter.
CONCLUSIONS: While TSA selectively suppresses a Th1 response by inducing apoptosis, it upregulates IL-4 expression probably by increasing histone H3 and H4 acetylation of the IL-4 gene promoter. We conclude that TSA can induce a Th1/Th2 balance in vivo and exert protective effects on CIA.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21305388     DOI: 10.1007/s10875-011-9508-8

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  41 in total

Review 1.  Functions of site-specific histone acetylation and deacetylation.

Authors:  Mona D Shahbazian; Michael Grunstein
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

2.  Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Authors:  J-H Lee; M L Choy; L Ngo; S S Foster; Paul A Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 3.  Role of cytokines in rheumatoid arthritis.

Authors:  M Feldmann; F M Brennan; R N Maini
Journal:  Annu Rev Immunol       Date:  1996       Impact factor: 28.527

4.  Histone deacetylase activities are required for innate immune cell control of Th1 but not Th2 effector cell function.

Authors:  Jennifer L Brogdon; Yongyao Xu; Susanne J Szabo; Shaojian An; Francis Buxton; Dalia Cohen; Qian Huang
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

5.  Phenotypic alterations of dendritic cells are involved in suppressive activity of trichosanthin-induced CD8+CD28- regulatory T cells.

Authors:  Baolong Wang; Zhijun Jiao; Xiaoyi Shao; Liming Lu; Neng Yang; Xiaorong Zhou; Lijun Xin; Yun Zhou; Kuang-Yen Chou
Journal:  J Immunol       Date:  2010-05-24       Impact factor: 5.422

6.  Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

Authors:  L M Butler; D B Agus; H I Scher; B Higgins; A Rose; C Cordon-Cardo; H T Thaler; R A Rifkind; P A Marks; V M Richon
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

7.  Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts.

Authors:  James S Chen; Douglas V Faller
Journal:  J Cell Physiol       Date:  2005-01       Impact factor: 6.384

Review 8.  Targeting lymphocyte activation to treat rheumatoid arthritis.

Authors:  Géraldine Falgarone; Luca Semerano; Sandrine Rullé; Marie-Christophe Boissier
Journal:  Joint Bone Spine       Date:  2009-06-16       Impact factor: 4.929

9.  Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model.

Authors:  Y Nasu; K Nishida; S Miyazawa; T Komiyama; Y Kadota; N Abe; A Yoshida; S Hirohata; A Ohtsuka; T Ozaki
Journal:  Osteoarthritis Cartilage       Date:  2008-01-15       Impact factor: 6.576

10.  The histone deacetylase inhibitor Trichostatin A modulates CD4+ T cell responses.

Authors:  José Manuel Afonso Moreira; Peter Scheipers; Poul Sørensen
Journal:  BMC Cancer       Date:  2003-11-09       Impact factor: 4.430

View more
  10 in total

1.  Class I and II histone deacetylase inhibition by ITF2357 reduces SLE pathogenesis in vivo.

Authors:  Nicole L Regna; Cristen B Chafin; Sarah E Hammond; Abdul G Puthiyaveetil; David L Caudell; Christopher M Reilly
Journal:  Clin Immunol       Date:  2014-01-15       Impact factor: 3.969

2.  [Prophylactic administration of all-trans retinoic acid alleviates inflammation in rats with collagen-induced arthritis].

Authors:  Xiang Zeng; Jing-Yan Shan; Yang Liu; Yan-Hua Ning; Xue-Jian Xie; Yu-Yan Shen; Jie Song; Yun Li
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2016-02-20

3.  Histone deacetylases inhibitor Trichostatin A ameliorates DNFB-induced allergic contact dermatitis and reduces epidermal Langerhans cells in mice.

Authors:  Yu-Ling Shi; Jun Gu; Jang-June Park; Jun-Yang Park; Ying-Ping Xu; Fu-Shin Yu; Li Zhou; Qing-Sheng Mi
Journal:  J Dermatol Sci       Date:  2012-09-07       Impact factor: 4.563

4.  T cells lacking HDAC11 have increased effector functions and mediate enhanced alloreactivity in a murine model.

Authors:  David M Woods; Karrune V Woan; Fengdong Cheng; Andressa L Sodré; Dapeng Wang; Yongxia Wu; Zi Wang; Jie Chen; John Powers; Javier Pinilla-Ibarz; Yu Yu; Ya Zhang; Xuefeng Wu; Xiaoyan Zheng; Jeffrey Weber; Wayne W Hancock; Edward Seto; Alejandro Villagra; Xue-Zhong Yu; Eduardo M Sotomayor
Journal:  Blood       Date:  2017-05-26       Impact factor: 22.113

Review 5.  FOXP3: genetic and epigenetic implications for autoimmunity.

Authors:  Hiroto Katoh; Pan Zheng; Yang Liu
Journal:  J Autoimmun       Date:  2013-01-11       Impact factor: 7.094

6.  Increased expression of Th17 cytokines and interleukin-22 correlates with disease activity in pristane-induced arthritis in rats.

Authors:  Bo Wang; Panpan Zhao; Yan Zhou; Liesu Meng; Wenhua Zhu; Congshan Jiang; Linyu Wang; Yongsong Cai; Shemin Lu; Weikun Hou
Journal:  PLoS One       Date:  2017-11-28       Impact factor: 3.240

7.  HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics.

Authors:  Andressa S Laino; B C Betts; A Veerapathran; I Dolgalev; A Sarnaik; S N Quayle; S S Jones; J S Weber; David M Woods
Journal:  J Immunother Cancer       Date:  2019-02-06       Impact factor: 13.751

Review 8.  Immunomodulatory Effects of Histone Deacetylation Inhibitors in Graft-vs.-Host Disease After Allogeneic Stem Cell Transplantation.

Authors:  Xiaoxiao Xu; Xiaoqin Li; Yanmin Zhao; He Huang
Journal:  Front Immunol       Date:  2021-02-24       Impact factor: 7.561

Review 9.  Pharmacological insights into autophagy modulation in autoimmune diseases.

Authors:  Ming-Yue Wu; Er-Jin Wang; Du Feng; Min Li; Richard D Ye; Jia-Hong Lu
Journal:  Acta Pharm Sin B       Date:  2021-03-22       Impact factor: 11.413

10.  Therapeutic Effect of Xuebijing, a Traditional Chinese Medicine Injection, on Rheumatoid Arthritis.

Authors:  Shutong Li; Hongxing Wang; Qinbao Sun; Bin Liu; Xiaotian Chang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-28       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.